Anzeige
Mehr »
Login
Sonntag, 11.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Kurseskalation am Montag? Diese Gamechanger-News macht es möglich!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PGY6 ISIN: US00211Y5069 Ticker-Symbol: HQ10 
Tradegate
09.04.21
16:37 Uhr
3,040 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ARCA BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
ARCA BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,0003,08010.04.
3,0203,08009.04.

Aktuelle News zur ARCA BIOPHARMA Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.03.ARCA biopharma reports FY results6
ARCA BIOPHARMA Aktie jetzt für 0€ handeln
18.03.ARCA biopharma, Inc. - 8-K, Current Report2
18.03.ARCA biopharma, Inc.: ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update8
18.03.ARCA biopharma, Inc. - 10-K, Annual Report2
17.12.20ARCA biopharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans18
10.12.20ARCA biopharma, Inc. - 8-K, Current Report5
09.12.20ARCA biopharma, Inc.: ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders4
24.11.20ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment19
23.11.20ARCA Biopharma's AB201 for COVID-19 Gets Fast Track9
23.11.20ARCA biopharma, Inc.: AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation5
02.11.20ARCA biopharma, Inc. - 10-Q, Quaterly Report3
02.11.20ARCA biopharma reports Q3 results4
02.11.20ARCA biopharma, Inc.: ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update8
12.08.20ARCA biopharma, Inc.: ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19374ARCA anticipates filing an IND for AB201 for COVID-19 in September 2020 and initiating Phase 2B clinical testing as early as Q4 2020 WESTMINSTER, CO / ACCESSWIRE / August 12, 2020 / ARCA biopharma...
► Artikel lesen
26.05.20European Nucleic Acid Testing/NAT Market 2020: Sales and Market Shares of Major Suppliers Including Abbott, Arca Biopharma, Biokit and Shimadzu - ResearchAndMarkets.com1.060The "2020 Europe Nucleic Acid Testing/NAT Market: Sales and Market Shares of Major Suppliers" report has been added to ResearchAndMarkets.com's offering. This unique report provides European...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,7